Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Stage IIIb or Stage IV Non-Small Cell Lung Cancer as First Line Therapy

NCT00005091 is registered in ClinicalTrials.gov with Daiichi Pharmaceuticals as lead sponsor.

NCT NCT00005091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00005091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Stage IIIb or Stage IV Non-Small Cell Lung Cancer as First Line Therapy
Lead sponsor
Daiichi Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
February 28, 1999
Completion date
August 31, 2003
Enrollment
Not reported
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer